This is a clinical research trial that will evaluate whether an investigational drug called ixekizumab (given by injection) is safe and effective in children and young adults with moderate to severe plaque psoriasis. For more information, please call Abby Powell at (843) 792-6690.
Subjects are being asked to volunteer for this research study because they have been diagnosed with Dermatomyositis (DM). This study will test the safety and effectiveness of the investigational new drug, IMO-8400. Subjects will receive a subcutaneous injection of the study drug or placebo once a week for up to 24 weeks during the study. Subjects will complete a total of 27 visits over the course of 32 weeks. After the baseline visit, subjects will have the option of having a visiting nurse (who has been trained in the protocol and approved by the Sponsor) conduct the intervening weekly study visits 2-25 outside of the clinic (e.g., at your home or workplace) rather than coming in to clinic for injections.
This study, comprised of an initial 12 month double-blind treatment phase of abatacept 125mg injected once a week vs placebo, followed by six month open label treatment phase, is designed to evaluate safety and effectiveness of the study drug, in subjects with diffuse systemic sclerosis.
Individuals with venous leg and diabetic foot ulcers often find these ulcers take a long time to heal and when they do, sometimes they come back. These ulcers can be quite painful making it hard to work, sleep and go about one's day to day activities. You will be asked to do a self-care routine of taking the temperature of the skin where the leg or foot ulcer just healed with a special thermometer and applying a small cooling gel patch over this skin. We want to know if this routine will prevent the ulcer from coming back, help you to become more active, and improve the quality of your life.
This study will test a low intensity foot exercise program for people with lower leg ulcers and who have problems with walking to see if it improves the condition of the legs. A small activity monitoring tracker called an accelerometer will be placed on the foot during the exercises that are to be done in the home for about 6 weeks. The tracker sends movement information to a cell phone that lets you and your doctor know about improvements in the foot movements. Better foot movements help condition the muscles and joints and may improve activity such as walking and getting up from a chair.
Keloid disease predominantly affects African Americans, Hispanics and some Asians. Keloid disease is characterized by an overgrowth of an area of the skin following some injury to that same skin area. It is unknown why this occurs. However, we believe that differences in Vitamin D along with dysfunction in certain immune system receptors can lead to keloid disease. To further understand this process we intend to study the cells (fibroblasts) in the skin that are affected by Vitamin D and examine the specific immune proteins.